Tango Therapeutics Income Before Tax Over Time
| TNGX Stock | USD 3.52 0.17 4.61% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tango Therapeutics Performance and Tango Therapeutics Correlation. Tango |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tango Therapeutics. If investors know Tango will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tango Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Revenue Per Share 0.402 | Quarterly Revenue Growth 0.082 | Return On Assets (0.22) | Return On Equity (0.49) |
The market value of Tango Therapeutics is measured differently than its book value, which is the value of Tango that is recorded on the company's balance sheet. Investors also form their own opinion of Tango Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tango Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tango Therapeutics' market value can be influenced by many factors that don't directly affect Tango Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tango Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tango Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tango Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Before Tax Analysis
Compare Tango Therapeutics and related stocks such as Third Harmonic Bio, Cullinan Oncology LLC, and Edgewise Therapeutics Income Before Tax Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THRD | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (29.6 M) | (35.2 M) | (30.8 M) | (32.4 M) |
| CGEM | (704.7 K) | (704.7 K) | (704.7 K) | (704.7 K) | (130.5 K) | (109.5 K) | (316.7 K) | (14.2 M) | (14.2 M) | (21.7 M) | (59.5 M) | (67.5 M) | 151.3 M | (169.2 M) | (160.8 M) |
| EWTX | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (17.1 M) | (42.8 M) | (19.4 M) | (100.2 M) | (95.2 M) |
| RLYB | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (24.9 M) | (45.5 M) | (65.6 M) | (74.6 M) | (70.8 M) |
| GLUE | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (35.9 M) | (74 M) | (108.5 M) | (135 M) | (128.3 M) |
| CNTB | (168.6 M) | (168.6 M) | (168.6 M) | (168.6 M) | (168.6 M) | (168.6 M) | (168.6 M) | (168.6 M) | (168.6 M) | (168.6 M) | (119.4 M) | (204.9 M) | (116.1 M) | (59.4 M) | (62.4 M) |
| TYRA | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (9.3 M) | (26.3 M) | (55.3 M) | (69.1 M) | (65.7 M) |
| RAPT | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (29.1 M) | (36.1 M) | (42.3 M) | (51.9 M) | (69.2 M) | (83.8 M) | (116.8 M) | (111 M) |
| XLO | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (55.2 M) | (75.8 M) | (88.2 M) | (76.4 M) | (80.2 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (68.3 M) |
| FHTX | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (51.1 M) | (68.8 M) | (101.3 M) | (108.9 M) | (94.2 M) | (98.9 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (36.6 M) | (45 M) | (101.9 M) | (87.3 M) | (82.9 M) |
| KYMR | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (41.2 M) | (45.6 M) | (100.2 M) | (154.8 M) | (147 M) | (139.6 M) |
| NRIX | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (21.5 M) | (63.8 M) | (117.1 M) | (180.4 M) | (143.9 M) | (129.6 M) | (136 M) |
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (52 M) | (108.5 M) | (187.1 M) | (249.1 M) | (439.9 M) | (417.9 M) |
| BDTX | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (8.9 M) | (35.3 M) | (67.3 M) | (125.6 M) | (88.9 M) | (82.4 M) | (86.6 M) |
| PASG | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (45.6 M) | (112.2 M) | (185.4 M) | (136.1 M) | (102.1 M) | (107.2 M) |
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (75.3 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (324.9 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (32.3 M) | (52.2 M) | (85.8 M) | (101.1 M) | (104.7 M) | (99.5 M) |
| PLRX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (631 K) | (41.5 M) | (19.7 M) | (123.3 M) | (161.3 M) | (153.3 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (70.3 M) | (119.3 M) | (191 M) | (251 M) | (363.9 M) | (345.7 M) |
Tango Therapeutics and related stocks such as Third Harmonic Bio, Cullinan Oncology LLC, and Edgewise Therapeutics Income Before Tax description
Income Before Tax which can also be referred as pre-tax income is reported on Tango Therapeutics income statement and is an important metric when analyzing Tango Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.My Equities
My Current Equities and Potential Positions
| Tango Therapeutics | TNGX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.52
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.